Mechanistically, in addition to amplification, HER2 somatic mutation is another mechanism to activate HER2 in breast cancer, with somatic mutations clustered in the extracellular domain of HER2 protein (20%) and the tyrosine kinase domain (68%) (Bose et al., 2013). This evidence concerns the gene ERBB2 and breast carcinoma.